Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation

Jacob Alexander, James D. Lord, Matthew M. Yeh, Carlos Cuevas, Ramasamy Bakthavatsalam, Kris V. Kowdley – 30 January 2008 – Orthotopic liver transplantation (OLT) is the only effective treatment for end‐stage liver disease due to primary sclerosing cholangitis (PSC). Recurrence of PSC has recently emerged as a leading cause of allograft failure in the long term. There is limited data on risk factors for recurrence of PSC. We performed a retrospective analysis of 69 consecutive patients who underwent a first OLT for PSC over a 14‐year period.

Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction

Ashokkumar Jain, Rajeev Sharma, Charlotte Ryan, Georgious Tsoulfas, Mark Orloff, Peter Abt, Randeep Kashyap, Pam Batzold, Lisa Sauberman, Saman Safadjou, Maureen Graham, Adel Bozorgzadeh – 30 January 2008 – With the current immunosuppressive regimens, graft loss secondary to immunological reasons after successful liver transplantation is a rarity; acute rejections, however, do occur, with the majority of them being steroid‐responsive.

Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation

Evangelos Cholongitas, Vibhakorn Shusang, George V. Papatheodoridis, Laura Marelli, Pinelopi Manousou, Nancy Rolando, David Patch, Keith Rolles, Brian Davidson, Andrew K. Burroughs – 30 January 2008 – Liver transplantation (LT) is the only therapeutic option for end‐stage primary sclerosing cholangitis (PSC), but PSC can recur (rPSC) in some patients after LT. The aim of our study was to evaluate the risk factors associated with rPSC. Between 1989 and 2004, 69 patients receiving transplantation for PSC (42 male, mean age 41.9 yr).

Subscribe to